Pfizer RSV vaccine under the microscope: does it shield seniors from severe illness?
NCT ID NCT06077968
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews medical records to see how effective Pfizer's ABRYSVO vaccine is at preventing severe RSV lung infections in adults 60 and older. Researchers will analyze existing health data from routine doctor visits over several years. No new treatments or active participation are required.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUSES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.